Hypertension and Excess Risk for Severe COVID-19 Illness Despite Booster Vaccination
Open Access
- 20 July 2022
- journal article
- letter
- Published by Wolters Kluwer Health in Hypertension
- Vol. 79 (10) , E132-E134
Abstract
No abstract availableKeywords
This publication has 5 references indexed in Scilit:
- Risk Factors for Severe COVID-19 Outcomes Among Persons Aged ≥18 Years Who Completed a Primary COVID-19 Vaccination Series — 465 Health Care Facilities, United States, December 2020–October 2021MMWR. Morbidity and Mortality Weekly Report, 2022
- Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 MonthsNew England Journal of Medicine, 2021
- Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational studyThe Lancet, 2021
- Mortality-related risk factors of COVID-19: a systematic review and meta-analysis of 42 studies and 423,117 patientsBMC Infectious Diseases, 2021
- Hypertension delays viral clearance and exacerbates airway hyperinflammation in patients with COVID-19Nature Biotechnology, 2020